SOTIO Entered into a License Agreement with Synaffix to Expand ADC Pipeline
Shots:
- Synaffix will receive ~$740M incl. signature, target nomination & milestones along with additional royalties on commercial sales & lead the manufacturing of components that are specifically related to its proprietary technologies
- SOTIO will be responsible for the research, development & commercialization of the ADCs & will gain access to Synaffix's ADC technologies, GlycoConnect, HydraSpace & toxSYN linker-payloads in an initial ADC program with the option to expand research and commercial licenses into 2 additional programs
- The collaboration combines Sotio’s deep expertise in solid tumor drug development with Synaffix’s clinical-stage platform technology to develop innovations for patients' benefit
Ref: PR Newswire | Image: SOTIO
Related News:- SOTIO Reports First Patient Dosing of Nanrilkefusp Alfa in P-II Trial (AURELIO-05) for Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
